Aptamers for personal health care applications
Inventors
Velasquez, Juan Esteban • Rupard, Spencer Christopher • Trejo, Amy Violet • PITZ, Adam Michael • Schmeichel, Kelly Lee • Swigart, Erin Nicole • Penner, Gregory Allen • NAMANJA-MAGLIANO, Hilda Andamiche • Wagner, Matthew Scott
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12584135-B2
Publication Date
2026-03-24
Expiration Date
Abstract
An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).
Core Innovation
The invention provides an aptamer composition that binds intercellular adhesion molecule 1 (ICAM-1). The aptamer composition comprises at least one oligonucleotide consisting of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof, and is configured to reduce the binding of one or more human rhinoviruses to ICAM-1.
The aptamer composition includes at least one oligonucleotide comprising from about 30 to about 60 nucleotides truncated from parent oligonucleotides selected from SEQ ID NO: 1 to SEQ ID NO: 200. Truncated aptamers are described as having a conserved secondary-structure architecture including double-stranded stems, hairpin/internal loops, and 5′/3′ dangling ends, and conserved sequence motifs are also identified within the truncated oligonucleotides.
Personal health care compositions and methods of inhibiting human rhinovirus infection are also described. The method inhibits human rhinovirus infection by inhibiting binding of the human rhinovirus to the ICAM-1 of epithelial cells, using the same ICAM-1-binding aptamer composition.
Claims Coverage
The independent claims cover three related aspects: an ICAM-1-binding truncated aptamer composition for reducing rhinovirus binding to ICAM-1, a personal health care composition containing that aptamer composition, and a method of inhibiting human rhinovirus infection by applying the aptamer composition to epithelial cells. Across these independent claims, the main inventive features are the ICAM-1-binding truncated oligonucleotide aptamers (30–60 nucleotides from specified parent SEQ ID NO: 1 to SEQ ID NO: 200) and their functional use in reducing rhinovirus binding and infection via ICAM-1.
Truncated ICAM-1-binding rhinovirus inhibitory aptamer composition
An aptamer composition comprising at least one oligonucleotide consisting of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof, wherein the aptamer composition has binding affinity for intercellular adhesion molecule 1 (ICAM-1) and is configured to reduce the binding of one or more human rhinoviruses to ICAM-1, wherein the aptamer composition comprises at least one oligonucleotide comprising from about 30 to about 60 nucleotides truncated from parent oligonucleotides selected from SEQ ID NO: 1 to SEQ ID NO: 200.
Personal health care composition with ICAM-1-binding truncated rhinovirus inhibitory aptamer composition
Personal health care composition comprising an aptamer composition comprising at least one oligonucleotide consisting of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof, wherein the aptamer composition has a binding affinity for intercellular adhesion molecule 1 (ICAM-1) and is configured to reduce the binding of one or more human rhinoviruses to ICAM-1, and wherein the aptamer composition comprises at least one oligonucleotide comprising from about 30 to about 60 nucleotides truncated from parent oligonucleotides selected from SEQ ID NO: 1 to SEQ ID NO: 200.
Method of inhibiting rhinovirus infection by applying ICAM-1-binding truncated aptamer composition
A method of inhibiting human rhinovirus infection by inhibiting binding of the human rhinovirus to ICAM-1 of epithelial cells comprising applying an aptamer composition comprising at least one oligonucleotide consisting of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof, wherein the aptamer composition has binding affinity for intercellular adhesion molecule 1 (ICAM-1) and is configured to reduce the binding of one or more human rhinoviruses to ICAM-1, and wherein the aptamer composition comprises at least one oligonucleotide comprising from about 30 to about 60 nucleotides truncated from parent oligonucleotides selected from SEQ ID NO: 1 to SEQ ID NO: 200.
Across the independent claims, coverage centers on ICAM-1-binding aptamer compositions that include truncated oligonucleotides of about 30 to about 60 nucleotides derived from parent oligonucleotides selected from SEQ ID NO: 1 to SEQ ID NO: 200, with the aptamers configured to reduce binding of one or more human rhinoviruses to ICAM-1. The claims extend this aptamer concept to a personal health care composition and to a method of inhibiting human rhinovirus infection by preventing rhinovirus binding to ICAM-1 on epithelial cells.
Stated Advantages
Reduce the binding of one or more human rhinoviruses to intercellular adhesion molecule 1 (ICAM-1).
Inhibit human rhinovirus infection by inhibiting binding of the human rhinovirus to ICAM-1 of epithelial cells.
Documented Applications
Personal health care composition for delivery to the upper respiratory tract, including nasal cavity and throat.
Inhibiting human rhinovirus infection by inhibiting viral binding to ICAM-1 on epithelial cells, including upper respiratory tract epithelial cells delivered by spraying.
Interested in licensing this patent?